4-Fluor-2-methyl-1-nitrosobenzol | 69745-27-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Fluor-2-methyl-1-nitrosobenzol
• 英文别名: 4-Fluoro-2-methyl-1-nitrosobenzene
• CAS: 69745-27-3
• 化学式: C₇H₆FNO
• 分子量: 139.129
• InChiKey: OMFRSHOBWFIKTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲基溴化镁 、 对氟硝基苯 生成 4-Fluor-2-methyl-1-nitrosobenzol
  参考文献：
  名称：

  Selectivity of attack in nucleophilic alkylation of nitroarenes with Grignard reagents. Reactivity of some substituted nitrobenzenes and nitronaphthalenes

  摘要：

  DOI：

  10.1021/jo01327a009

文献信息

• [EN] PROGNOSTIC BIOMARKERS FOR TTK INHIBITOR CHEMOTHERAPY<br/>[FR] BIOMARQUEURS PRONOSTIQUES POUR CHIMIOTHÉRAPIE BASÉE SUR UN INHIBITEUR DE TTK
  申请人：NETHERLANDS TRANSLATIONAL RES CENTER B V

  公开号：WO2016166255A1

  公开（公告）日：2016-10-20

  The present invention provides a method for identifying a tumor - in a human individual or in an animal - that is susceptible to treatment with a TTK inhibitor, said method comprising: a] providing a sample of a tumor; b] determining the presence of a mutated CTNNB1 gene in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 gene indicates that the tumor is susceptible to treatment with a TTK inhibitor. In an alternative aspect, step b] of the above defined method is replaced by the step of determining the presence of a mutated CTNNB1 protein in said tumor sample, wherein said mutation is located in exon 3 of CTNNB1 and whereby the presence of a mutated CTNNB1 protein indicates that the tumor is susceptible to treatment with a TTK inhibitor. In a further alternative, step b] comprises determining an altered expression of a CTNNB1 regulated gene, whereby an altered expression of a CTNNB1 regulated gene indicates that the tumor is susceptible to treatment with a TTK inhibitor.

  本发明提供了一种用于识别易受TTK抑制剂治疗的人体或动物肿瘤的方法，所述方法包括：a] 提供肿瘤样本；b] 确定肿瘤样本中是否存在突变的CTNNB1基因，其中所述突变位于CTNNB1的第3外显子中，并且存在突变的CTNNB1基因表明肿瘤易受TTK抑制剂治疗。在另一种方面，上述定义方法的步骤b] 被替换为确定肿瘤样本中是否存在突变的CTNNB1蛋白，其中所述突变位于CTNNB1的第3外显子中，并且存在突变的CTNNB1蛋白表明肿瘤易受TTK抑制剂治疗。在进一步的替代方案中，步骤b] 包括确定CTNNB1调控基因的表达改变，其中CTNNB1调控基因的表达改变表明肿瘤易受TTK抑制剂治疗。
• Bicyclic And Tricyclic Compounds As KAT II Inhibitors
  申请人：Claffey Michelle M.

  公开号：US20100324043A1

  公开（公告）日：2010-12-23

  Compounds of Formula X: wherein A, X, Y, Z, R 5 , R 6a , and R 6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.

  化合物X的结构如下：其中A、X、Y、Z、R5、R6a和R6b的定义如本文所述，并且其药用盐被描述为用于治疗与精神分裂症及其他哺乳动物，包括人类，相关的认知缺陷的化合物，以及其他神经退行性和/或神经系统疾病。
• METHODS FOR TREATING RETROVIRAL INFECTIONS
  申请人：Dunn James Patrick

  公开号：US20100041648A1

  公开（公告）日：2010-02-18

  The present invention provides compositions for treating an HIV infection comprising administering a compound according to formula I where Ar, R 1 -R 5 , R 11c and X 1 are as defined herein with at least one carrier, excipient or diluent.

  本发明提供了用于治疗HIV感染的组合物，其包括按照式I给出的化合物与至少一种载体、赋形剂或稀释剂一起使用，其中Ar、R1-R5、R11c和X1的定义如本文所述。
• Medicaments Comprising Carbonyl Compounds, And The Use Thereof
  申请人：Cezanne Bertram

  公开号：US20080003214A1

  公开（公告）日：2008-01-03

  Use of compounds of the formula (I) in which D, E, G, W, X, Y, T, R 1 and R 2 have the meaning indicated in Patent Claim 1 , for the prophylaxis and/or therapy of thromboembolic diseases

  使用式(I)中D、E、G、W、X、Y、T、R1和R2所表示的含义如专利要求书1所述，用于预防和/或治疗血栓栓塞疾病。
• 4-Aryl-2-Amino-Pyrimidnes or 4-Aryl-2-Aminoalkyl-Pyrimidines as Jak-2 Modulators and Methods of Use
  申请人：Mann Grace

  公开号：US20090298830A1

  公开（公告）日：2009-12-03

  This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R 1 , R 2 , R 25 , and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本发明涉及某些JAK-2的嘧啶衍生物抑制剂，具有公式（I）：其中D、E、L、Z、R1、R2、R25和n1如规范中所定义，其药学上可接受的盐，其制药组合物以及其使用方法。